Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Sarah S. Bacus"'
KRAS gene mutation is linked to poor prognosis and resistance to therapeutics in non–small cell lung cancer (NSCLC). In this study, we have explored the possibility of exploiting inherent differences in KRAS-mutant cell metabolism for treatment. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6224b879257a08264438939e97acf6d
https://doi.org/10.1158/1535-7163.c.6536542.v1
https://doi.org/10.1158/1535-7163.c.6536542.v1
PDF - 68K, Normalized basal gene expression microarray data for non-squamous NSCLC NCI60 cell lines were grouped according to KRAS mutation status. Genes showing significant differences in expression between KRAS mutant and KRAS wildtype cells were a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a52000bf10937f7e1bb188611ab2d0f9
https://doi.org/10.1158/1535-7163.22500685
https://doi.org/10.1158/1535-7163.22500685
PDF - 75K, Normalized basal gene expression microarray data for non-squamous NSCLC NCI60 cell lines were grouped according to KRAS mutation status. Genes showing significant differences in expression between KRAS mutant and KRAS wildtype cells were a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32970d1854abf60ef96c4f6544ff989a
https://doi.org/10.1158/1535-7163.22500688.v1
https://doi.org/10.1158/1535-7163.22500688.v1
PDF - 69K, Normalized basal gene expression microarray data for non-squamous NSCLC NCI60 cell lines were grouped according to KRAS mutation status. Genes showing significant differences in expression between KRAS mutant and KRAS wildtype cells were a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103fa5a94022bf8a7d1b9ac3883e907d
https://doi.org/10.1158/1535-7163.22500682.v1
https://doi.org/10.1158/1535-7163.22500682.v1
Publikováno v:
Experimental and Molecular Pathology. 109:1-15
Recent FDA approvals of immunotherapy for NSCLC provide patients new treatment options, and these approvals also highlight the importance of the immune response in cancer treatment. While immunotherapy provides patients a new treatment option, the th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9d3cd18de1aa44d68d249e2035490c
https://doi.org/10.1016/j.yexmp.2019.04.004
https://doi.org/10.1016/j.yexmp.2019.04.004
Autor:
Anna Biernacka, Min Yi, W. Fraser Symmans, Kwok-Leung Cheung, Cansu Karakas, Opoku Adjapong, Kim Anh Do, Gabriel N. Hortobagyi, Sarah S. Bacus, Khandan Keyomarsi, Kelly K. Hunt, Melissa L. Bondy, Ian O. Ellis, Min Jin Ha, Patricia A. Thompson, Aysegul A. Sahin
Publikováno v:
Clinical Cancer Research. 23:2991-3002
Purpose: Low molecular weight cyclin E (LMW-E) detected by Western blot analysis predicts for reduced breast cancer survival; however, it is impractical for clinical use. LMW-E lacks a nuclear localization signal that leads to accumulation in the cyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65115c97ea2d94d2d8fb69e93e815a10
https://doi.org/10.1158/1078-0432.ccr-16-2217
https://doi.org/10.1158/1078-0432.ccr-16-2217
Autor:
Sarah S. Bacus, Diarmuid Moran, Massimo Cristofanilli, Siân Jones, Christopher A. Hamm, Victor E. Velculescu, Karen Pry, Patricia Trusk, Mark Sausen, Kakuturu Rao
Publikováno v:
Molecular Cancer Therapeutics. 15:1746-1756
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted next-g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72137e26cc9b2239513c2d83ec8995d
https://doi.org/10.1158/1535-7163.mct-15-0353
https://doi.org/10.1158/1535-7163.mct-15-0353
Autor:
Patricia Trusk, Diarmuid M. Moran, Scott A. Shell, Dominique R. Talbert, Kimberly R. Doherty, Sarah S. Bacus
Publikováno v:
Toxicology and Applied Pharmacology. 285:51-60
Safety pharmacology studies that evaluate new drug entities for potential cardiac liability remain a critical component of drug development. Current studies have shown that in vitro tests utilizing human induced pluripotent stem cell-derived cardiomy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf1fd0df5913495978e6804a9684d06
https://doi.org/10.1016/j.taap.2015.03.008
https://doi.org/10.1016/j.taap.2015.03.008
Publikováno v:
Journal of Cancer Therapy. :907-918
In recent years histone deacetylase inhibitors (HDACi’s) have emerged as promising therapeutics for cancer. While favorable responses to HDACi’s as single agents have been shown in several hematological malignancies, very little efficacy has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c4e2dfbf384761e2fd32d0763e5a058
https://doi.org/10.4236/jct.2013.44102
https://doi.org/10.4236/jct.2013.44102
Autor:
Aaron Rabinkov, Nir Ben-Chetrit, Alex Starr, Sarah S. Bacus, Chaluvally-Raghavan Pradeep, Wolfgang J. Köstler, Sara Lavi, Moshit Lindzen, Yosef Yarden, Silvia Carvalho
Publikováno v:
Oncogene
Epidermal growth factor (EGF)-like growth factors control tumor progression as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies targeting the cognate receptors, such as EGFR/ErbB-1 and the co-receptor HER2/ErbB-2, are w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd57627e75110e6beb45be8d4470243
https://doi.org/10.1038/onc.2011.518
https://doi.org/10.1038/onc.2011.518